A phase Ib clinical trial in newly diagnosed glioblastoma reported promising activity for a personalized neoantigen dendritic cell vaccine that pulses autologous dendritic cells with patient-specific neoantigens, according to findings published in Nature Communications. The approach targets tumor-specific mutation-derived neoantigens by generating an individualized cellular therapy for each participant. The study’s early-stage results focus on safety and initial immunologic and clinical signals in a population with historically poor outcomes. The trial is notable for translating personalized antigen selection into a practical dendritic cell manufacturing workflow for a difficult solid tumor setting, where immunotherapy responses have often been limited by tumor heterogeneity. For investors and partners, the publication strengthens the case for neoantigen-guided dendritic cell platforms and underscores the need to track how response durability and expansion cohorts perform as programs mature.